FAK Blockade Reprograms Ovarian Tumor Immunity via Omega-3 Signals in Mice

Overview

• Blocked FAK activity prompted tumor cells to release omega-3–rich particles that were taken up by macrophages.
• These signals drove macrophages to secrete CXCL13, drawing B and T cells and fostering tertiary lymphoid structures near tumors.
• In mouse experiments, combining an FAK inhibitor with low-dose chemotherapy and immunotherapy curbed tumor growth, boosted immune infiltration, and prolonged survival.
• High-grade serous ovarian cancers often overexpress FAK, a feature tied to poorer outcomes and ongoing interest in FAK-targeting drugs.
• The Cell Reports study by UC San Diego and Sanford Burnham Prebys remains preclinical, and the authors urge clinical testing of FAK–chemo–immunotherapy combinations.